Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1–34) from rat lungs
The aim of this work was to optimize the absorption of parathyroid hormone 1–34 (PTH) from the lungs by determining factors favoring its transport from the air spaces into the bloodstream. We simultaneously conducted pharmacokinetic and regional lung deposition studies in vivo in the rat following i...
Gespeichert in:
Veröffentlicht in: | Journal of pharmaceutical sciences 2004-05, Vol.93 (5), p.1241-1252 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1252 |
---|---|
container_issue | 5 |
container_start_page | 1241 |
container_title | Journal of pharmaceutical sciences |
container_volume | 93 |
creator | Codrons, Valérie Vanderbist, Francis Ucakar, Bernard Préat, Véronique Vanbever, Rita |
description | The aim of this work was to optimize the absorption of parathyroid hormone 1–34 (PTH) from the lungs by determining factors favoring its transport from the air spaces into the bloodstream. We simultaneously conducted pharmacokinetic and regional lung deposition studies in vivo in the rat following intratracheal administration of PTH in solution or dry powder form. Dry powders of PTH or albumin were prepared by spray-drying using lactose and dipalmitoylphosphatidylcholine (DPPC). Deposition in the trachea, peripheral, and central lobe sections was assessed after tissue grinding using albumin as a marker. The method of intratracheal instillation had a significant impact on PTH absorption from the lungs, and the deeper the deposition within the respiratory tract, the higher the absorption. Inhalation of the PTH powder resulted in high systemic bioavailability despite deposition of the formulation principally in upper airways. We demonstrated that the increased absorption resulted from DPPC that had permeation enhancer properties even though it was abundantly present locally in pulmonary surfactant. Optimization of PTH absorption from the lungs could be attained by targeting the peripheral lungs as well as codelivering DPPC. © 2004 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 93:1241–1252, 2004 |
doi_str_mv | 10.1002/jps.20053 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71815083</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354916315040</els_id><sourcerecordid>71815083</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4993-599d2c9fca6b511a18cbd85674b9b2fde4da7272755841de83f6299aeb1956203</originalsourceid><addsrcrecordid>eNp1kMtu1TAQhi0EoofCghdA3oDoIq3txE68rCp6oVVBKqhLy7EnHJckDnZSODveoW_Ik-A0h8sC5MVYmm_-0XwIPadknxLCDm6GuM8I4fkDtKKckUwQWj5Eq9RjWc4LuYOexHhDCBGE88doh3IiypKQFRrPukGbEfsGNz50U6tH53use4s7GNfexrk1TG3nex022ELrbiF9ZqiOPgz3_MzooMf1Jnhn8TpF-R7wa_rj-11e7OEm-A6nPm6n_lN8ih41uo3wbFt30cfjNx-OTrOLdydnR4cXmSmkzDMupWVGNkaLmlOqaWVqW3FRFrWsWWOhsLpk6XFeFdRClTeCSamhppILRvJd9GrJHYL_MkEcVeeigbbVPfgpqpJWyUSVJ3BvAU3wMQZo1BBcl-5VlKhZsUqK1b3ixL7Yhk51B_YPuXWagJdbQEej2ybo3rj4FycEJ2wOOli4r66Fzf83qrfvr36tzpYJF0f49ntCh89KlHnJ1fXliUrx9JifX6nrxOcLD0nyrYOgonHQG7AugBmV9e4fB_4ECO20bg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71815083</pqid></control><display><type>article</type><title>Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1–34) from rat lungs</title><source>MEDLINE</source><source>Wiley Online Library Journals【Remote access available】</source><source>Alma/SFX Local Collection</source><creator>Codrons, Valérie ; Vanderbist, Francis ; Ucakar, Bernard ; Préat, Véronique ; Vanbever, Rita</creator><creatorcontrib>Codrons, Valérie ; Vanderbist, Francis ; Ucakar, Bernard ; Préat, Véronique ; Vanbever, Rita</creatorcontrib><description>The aim of this work was to optimize the absorption of parathyroid hormone 1–34 (PTH) from the lungs by determining factors favoring its transport from the air spaces into the bloodstream. We simultaneously conducted pharmacokinetic and regional lung deposition studies in vivo in the rat following intratracheal administration of PTH in solution or dry powder form. Dry powders of PTH or albumin were prepared by spray-drying using lactose and dipalmitoylphosphatidylcholine (DPPC). Deposition in the trachea, peripheral, and central lobe sections was assessed after tissue grinding using albumin as a marker. The method of intratracheal instillation had a significant impact on PTH absorption from the lungs, and the deeper the deposition within the respiratory tract, the higher the absorption. Inhalation of the PTH powder resulted in high systemic bioavailability despite deposition of the formulation principally in upper airways. We demonstrated that the increased absorption resulted from DPPC that had permeation enhancer properties even though it was abundantly present locally in pulmonary surfactant. Optimization of PTH absorption from the lungs could be attained by targeting the peripheral lungs as well as codelivering DPPC. © 2004 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 93:1241–1252, 2004</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1002/jps.20053</identifier><identifier>PMID: 15067700</identifier><identifier>CODEN: JPMSAE</identifier><language>eng</language><publisher>Hoboken: Elsevier Inc</publisher><subject>absorption ; Absorption - drug effects ; Absorption - physiology ; Administration, Inhalation ; Animals ; Biological and medical sciences ; Chemistry, Pharmaceutical ; dipalmitoylphosphatidylcholine ; Drug Delivery Systems - methods ; General pharmacology ; human parathyroid hormone ; Humans ; inhalation dry powder ; Lung - drug effects ; Lung - metabolism ; Male ; Medical sciences ; Parathyroid Hormone - administration & dosage ; Parathyroid Hormone - pharmacokinetics ; Peptide Fragments - administration & dosage ; Peptide Fragments - pharmacokinetics ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; pulmonary deposition ; pulmonary drug delivery ; Rats ; Rats, Wistar</subject><ispartof>Journal of pharmaceutical sciences, 2004-05, Vol.93 (5), p.1241-1252</ispartof><rights>2004 Wiley-Liss, Inc.</rights><rights>Copyright © 2004 Wiley‐Liss, Inc.</rights><rights>2004 INIST-CNRS</rights><rights>Copyright 2004 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 93:1241-1252, 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4993-599d2c9fca6b511a18cbd85674b9b2fde4da7272755841de83f6299aeb1956203</citedby><cites>FETCH-LOGICAL-c4993-599d2c9fca6b511a18cbd85674b9b2fde4da7272755841de83f6299aeb1956203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjps.20053$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjps.20053$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27933,27934,45583,45584</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15665023$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15067700$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Codrons, Valérie</creatorcontrib><creatorcontrib>Vanderbist, Francis</creatorcontrib><creatorcontrib>Ucakar, Bernard</creatorcontrib><creatorcontrib>Préat, Véronique</creatorcontrib><creatorcontrib>Vanbever, Rita</creatorcontrib><title>Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1–34) from rat lungs</title><title>Journal of pharmaceutical sciences</title><addtitle>J. Pharm. Sci</addtitle><description>The aim of this work was to optimize the absorption of parathyroid hormone 1–34 (PTH) from the lungs by determining factors favoring its transport from the air spaces into the bloodstream. We simultaneously conducted pharmacokinetic and regional lung deposition studies in vivo in the rat following intratracheal administration of PTH in solution or dry powder form. Dry powders of PTH or albumin were prepared by spray-drying using lactose and dipalmitoylphosphatidylcholine (DPPC). Deposition in the trachea, peripheral, and central lobe sections was assessed after tissue grinding using albumin as a marker. The method of intratracheal instillation had a significant impact on PTH absorption from the lungs, and the deeper the deposition within the respiratory tract, the higher the absorption. Inhalation of the PTH powder resulted in high systemic bioavailability despite deposition of the formulation principally in upper airways. We demonstrated that the increased absorption resulted from DPPC that had permeation enhancer properties even though it was abundantly present locally in pulmonary surfactant. Optimization of PTH absorption from the lungs could be attained by targeting the peripheral lungs as well as codelivering DPPC. © 2004 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 93:1241–1252, 2004</description><subject>absorption</subject><subject>Absorption - drug effects</subject><subject>Absorption - physiology</subject><subject>Administration, Inhalation</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Chemistry, Pharmaceutical</subject><subject>dipalmitoylphosphatidylcholine</subject><subject>Drug Delivery Systems - methods</subject><subject>General pharmacology</subject><subject>human parathyroid hormone</subject><subject>Humans</subject><subject>inhalation dry powder</subject><subject>Lung - drug effects</subject><subject>Lung - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Parathyroid Hormone - administration & dosage</subject><subject>Parathyroid Hormone - pharmacokinetics</subject><subject>Peptide Fragments - administration & dosage</subject><subject>Peptide Fragments - pharmacokinetics</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>pulmonary deposition</subject><subject>pulmonary drug delivery</subject><subject>Rats</subject><subject>Rats, Wistar</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtu1TAQhi0EoofCghdA3oDoIq3txE68rCp6oVVBKqhLy7EnHJckDnZSODveoW_Ik-A0h8sC5MVYmm_-0XwIPadknxLCDm6GuM8I4fkDtKKckUwQWj5Eq9RjWc4LuYOexHhDCBGE88doh3IiypKQFRrPukGbEfsGNz50U6tH53use4s7GNfexrk1TG3nex022ELrbiF9ZqiOPgz3_MzooMf1Jnhn8TpF-R7wa_rj-11e7OEm-A6nPm6n_lN8ih41uo3wbFt30cfjNx-OTrOLdydnR4cXmSmkzDMupWVGNkaLmlOqaWVqW3FRFrWsWWOhsLpk6XFeFdRClTeCSamhppILRvJd9GrJHYL_MkEcVeeigbbVPfgpqpJWyUSVJ3BvAU3wMQZo1BBcl-5VlKhZsUqK1b3ixL7Yhk51B_YPuXWagJdbQEej2ybo3rj4FycEJ2wOOli4r66Fzf83qrfvr36tzpYJF0f49ntCh89KlHnJ1fXliUrx9JifX6nrxOcLD0nyrYOgonHQG7AugBmV9e4fB_4ECO20bg</recordid><startdate>200405</startdate><enddate>200405</enddate><creator>Codrons, Valérie</creator><creator>Vanderbist, Francis</creator><creator>Ucakar, Bernard</creator><creator>Préat, Véronique</creator><creator>Vanbever, Rita</creator><general>Elsevier Inc</general><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><general>American Pharmaceutical Association</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200405</creationdate><title>Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1–34) from rat lungs</title><author>Codrons, Valérie ; Vanderbist, Francis ; Ucakar, Bernard ; Préat, Véronique ; Vanbever, Rita</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4993-599d2c9fca6b511a18cbd85674b9b2fde4da7272755841de83f6299aeb1956203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>absorption</topic><topic>Absorption - drug effects</topic><topic>Absorption - physiology</topic><topic>Administration, Inhalation</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Chemistry, Pharmaceutical</topic><topic>dipalmitoylphosphatidylcholine</topic><topic>Drug Delivery Systems - methods</topic><topic>General pharmacology</topic><topic>human parathyroid hormone</topic><topic>Humans</topic><topic>inhalation dry powder</topic><topic>Lung - drug effects</topic><topic>Lung - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Parathyroid Hormone - administration & dosage</topic><topic>Parathyroid Hormone - pharmacokinetics</topic><topic>Peptide Fragments - administration & dosage</topic><topic>Peptide Fragments - pharmacokinetics</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>pulmonary deposition</topic><topic>pulmonary drug delivery</topic><topic>Rats</topic><topic>Rats, Wistar</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Codrons, Valérie</creatorcontrib><creatorcontrib>Vanderbist, Francis</creatorcontrib><creatorcontrib>Ucakar, Bernard</creatorcontrib><creatorcontrib>Préat, Véronique</creatorcontrib><creatorcontrib>Vanbever, Rita</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Codrons, Valérie</au><au>Vanderbist, Francis</au><au>Ucakar, Bernard</au><au>Préat, Véronique</au><au>Vanbever, Rita</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1–34) from rat lungs</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J. Pharm. Sci</addtitle><date>2004-05</date><risdate>2004</risdate><volume>93</volume><issue>5</issue><spage>1241</spage><epage>1252</epage><pages>1241-1252</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><coden>JPMSAE</coden><abstract>The aim of this work was to optimize the absorption of parathyroid hormone 1–34 (PTH) from the lungs by determining factors favoring its transport from the air spaces into the bloodstream. We simultaneously conducted pharmacokinetic and regional lung deposition studies in vivo in the rat following intratracheal administration of PTH in solution or dry powder form. Dry powders of PTH or albumin were prepared by spray-drying using lactose and dipalmitoylphosphatidylcholine (DPPC). Deposition in the trachea, peripheral, and central lobe sections was assessed after tissue grinding using albumin as a marker. The method of intratracheal instillation had a significant impact on PTH absorption from the lungs, and the deeper the deposition within the respiratory tract, the higher the absorption. Inhalation of the PTH powder resulted in high systemic bioavailability despite deposition of the formulation principally in upper airways. We demonstrated that the increased absorption resulted from DPPC that had permeation enhancer properties even though it was abundantly present locally in pulmonary surfactant. Optimization of PTH absorption from the lungs could be attained by targeting the peripheral lungs as well as codelivering DPPC. © 2004 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 93:1241–1252, 2004</abstract><cop>Hoboken</cop><pub>Elsevier Inc</pub><pmid>15067700</pmid><doi>10.1002/jps.20053</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3549 |
ispartof | Journal of pharmaceutical sciences, 2004-05, Vol.93 (5), p.1241-1252 |
issn | 0022-3549 1520-6017 |
language | eng |
recordid | cdi_proquest_miscellaneous_71815083 |
source | MEDLINE; Wiley Online Library Journals【Remote access available】; Alma/SFX Local Collection |
subjects | absorption Absorption - drug effects Absorption - physiology Administration, Inhalation Animals Biological and medical sciences Chemistry, Pharmaceutical dipalmitoylphosphatidylcholine Drug Delivery Systems - methods General pharmacology human parathyroid hormone Humans inhalation dry powder Lung - drug effects Lung - metabolism Male Medical sciences Parathyroid Hormone - administration & dosage Parathyroid Hormone - pharmacokinetics Peptide Fragments - administration & dosage Peptide Fragments - pharmacokinetics Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments pulmonary deposition pulmonary drug delivery Rats Rats, Wistar |
title | Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1–34) from rat lungs |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T13%3A55%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20formulation%20and%20methods%20of%20pulmonary%20delivery%20on%20absorption%20of%20parathyroid%20hormone%20(1%E2%80%9334)%20from%20rat%20lungs&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Codrons,%20Val%C3%A9rie&rft.date=2004-05&rft.volume=93&rft.issue=5&rft.spage=1241&rft.epage=1252&rft.pages=1241-1252&rft.issn=0022-3549&rft.eissn=1520-6017&rft.coden=JPMSAE&rft_id=info:doi/10.1002/jps.20053&rft_dat=%3Cproquest_cross%3E71815083%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71815083&rft_id=info:pmid/15067700&rft_els_id=S0022354916315040&rfr_iscdi=true |